Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis

X
Trial Profile

A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 05 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary) ; Corticosteroids
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms Liberty AD; LIBERTY AD PRE-SCHOOL
  • Sponsors Regeneron Pharmaceuticals; Sanofi
  • Most Recent Events

    • 01 Mar 2024 Results assessing clinical data of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitis published in the Pediatric Dermatology
    • 26 Feb 2024 Results of pooled analysis of LIBERTY AD PRESCHOOL,LIBERTY AD PEDS , LIBERTYAD ADOL , LIBERTY AD SOLO1,LIBERTYADSOLO2 reporting serum CCL17/TARC (human TARC Quantikine ELISA kit; R&D Systems) levels from patients with moderate-to-severe or severe AD, presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 09 Jan 2024 Results of pre-specified subgroup analysis of data for patients aged 6 months to 5 years with severe AD at baseline, published in the Advances in Therapy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top